home · filing · 0001485003-21-000152
8-K filed July 21, 2021, 7:59 PM ET
ticker CARM
CIK 0001485003
leadership
confidence high
sentiment positive
materiality 0.40
Sesen Bio appoints two new directors with regulatory and clinical expertise
Carisma Therapeutics Inc.
Peter K Honig, MD (former Pfizer global regulatory head) and Michael A.S. Jewett, MD (urologic oncologist and Order of Canada) elected to Board.
Board size increased from 5 to 7 members; both appointed effective July 20, 2021.
Each new director received initial option to purchase 185,000 shares at $3.86 per share.
Company reiterates on track for FDA decision on Vicineum BLA by PDUFA date August 18, 2021.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-07-20
Filed July 21, 2021, 7:59 PM ET
elected Peter K Honig, M.D. and Michael A.S. Jewett, M.D. to the Board
Effective 2021-07-20
Filed July 21, 2021, 7:59 PM ET
elected Peter K Honig, M.D. and Michael A.S. Jewett, M.D. to the Board
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael A.S. Jewett, M.D. was elected as Director at Carisma Therapeutics Inc..
Action elected
Role Director
Exact text from the filing
elected Peter K Honig, M.D. and Michael A.S. Jewett, M.D. to the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter K Honig, M.D. was elected as Director at Carisma Therapeutics Inc..
Action elected
Role Director
Exact text from the filing
elected Peter K Honig, M.D. and Michael A.S. Jewett, M.D. to the Board
View on SEC.gov
Source: SEC EDGAR
accession 0001485003-21-000152
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.